文献速递乳腺癌

艾立布林联合帕博利珠单抗对比艾立布林单药治疗HR阳性/HER2阴性转移性乳腺癌的随机临床试验

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

结果显示两组中位无进展生存期(4.1 vs 4.2个月)和客观缓解率(27% vs 34%)均无显著差异,联合组出现2例治疗相关死亡(免疫相关性结肠炎合并脓毒症)。

要点

  • 在HR阳性/ERBB2阴性转移性乳腺癌中,艾立布林联合帕博利珠单抗未改善无进展生存期。
  • 联合组与单药组客观缓解率分别为27%和34%,差异无统计学意义。
  • 联合组发生2例治疗相关死亡,均与免疫相关性结肠炎合并脓毒症有关。

核心结论

  • 在HR阳性、ERBB2阴性转移性乳腺癌患者中,无论意向治疗人群还是PD-L1阳性人群,艾立布林联合帕博利珠单抗相比艾立布林单药均未改善无进展生存期、客观缓解率或总生存期。

主要发现

  • PD-L1状态、肿瘤浸润淋巴细胞、肿瘤突变负荷及基因组改变与无进展生存期均无关联。

关键数值与推荐

  • PD-L1 22C3检测在65例存档肿瘤样本中进行,24例(37%)为PD-L1阳性。
  • 联合组发生2例治疗相关死亡,均归因于两药,死因为免疫相关性结肠炎合并脓毒症。

临床怎么用

  • 对于HR阳性、ERBB2阴性转移性乳腺癌,不推荐在艾立布林基础上常规联合帕博利珠单抗。
  • 联合免疫治疗时需警惕免疫相关性结肠炎等严重不良事件,尤其合并感染时。

局限性

  • PD-L1检测仅在65例存档样本中完成,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prior studies have shown that only a small proportion of patients with hormone receptor (HR)-positive metastatic breast cancer (MBC) experience benefit from programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors given as monotherapy. There are data suggesting that activity may be greater with combination strategies. OBJECTIVE: To compare the efficacy of eribulin plus pembrolizumab vs eribulin alone in patients with HR-positive, ERBB2 (formerly HER2)-negative MBC. DESIGN, SETTING, AND PARTICIPANTS: Multicenter phase 2 randomized clinical trial of patients with HR-positive, ERBB2-negative MBC who had received 2 or more lines of hormonal therapy and 0 to 2 lines of chemotherapy. INTERVENTIONS: Patients were randomized 1:1 to eribulin, 1.4 mg/m2 intravenously, on days 1 and 8 plus pembrolizumab, 200 mg/m2 intravenously, on day 1 of a 21-day cycle or eribulin alone. At time of progression, patients in the eribulin monotherapy arm could cross over and receive pembrolizumab monotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS). Secondary end points were objective response rate (ORR) and overall survival (OS). Exploratory analyses assessed the association between PFS and PD-L1 status, tumor-infiltrating lymphocytes (TILs), tumor mutational burden (TMB), and genomic alterations. RESULTS: Eighty-eight patients started protocol therapy; the median (range) age was 57 (30-76) years, median (range) number of prior lines of chemotherapy was 1 (0-2), and median (range) number of prior lines of hormonal therapy was 2 (0-5). Median follow-up was 10.5 (95% CI, 0.4-22.8) months. Median PFS and ORR were not different between the 2 groups (PFS, 4.1 vs 4.2 months; hazard ratio, 0.80; 95% CI, 0.50-1.26; P = .33; ORR, 27% vs 34%, respectively; P = .49). Fourteen patients started crossover treatment with pembrolizumab; 1 patient experienced stable disease. All-cause adverse events occurred in all patients (grade ≥3, 65%) including 2 treatment-related deaths in the combination group, both from immune-related colitis in the setting of sepsis, attributed to both drugs. The PD-L1 22C3 assay was performed on archival tumor samples in 65 patients: 24 (37%) had PD-L1-positive tumors. Analysis indicated that PD-L1 status, TILs, TMB, and genomic alterations were not associated with PFS. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with HR-positive, ERBB2-negative MBC, the addition of pembrolizumab to eribulin did not improve PFS, ORR, or OS compared with eribulin alone in either the intention-to-treat or PD-L1-positive populations. Further efforts to explore the benefits of adding checkpoint inhibition to chemotherapy among less heavily pretreated patients are needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03051659.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tolaney SM, Barroso-Sousa R, Keenan T, et al. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32880602. doi:10.1001/jamaoncol.2020.3524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。